A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Antidepressants treat major depressive disorder (MDD) with the burden of associated side effects and difficulties with compliance. The purpose of this article is to review the efficacy and effectiveness of antidepressants for MDD. METHODS: The authors conducted a focused review of selected key issues and references relevant to the clinically relevant pharmacologic treatment of MDD. Principles of treatment are reviewed. Antidepressants reviewed include SSRIs, mixed norepinephrine or serotonin uptake inhibitors, dopamine or norepinephrine uptake inhibitors, norepinephrine uptake inhibitors, antidepressants with mixed properties, and monoamine oxidase inhibitors. Augmentation and psychotherapy strategies are reviewed. RESULTS: Antidepressant efficacy has been established in randomized clinical trials and effectiveness studies for acute and long-term treatment, but many patients do not achieve remission. Augmentation strategies and focused psychotherapy can be helpful. CONCLUSIONS: Antidepressants help most patients with MDD but some are resistant to treatment and have a difficult long-term course.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the reason that we set antidepressant users who had been prescribed at least 30 days is because depressive symptoms get improved within this period of time [36]”
From Risk analysis of use of different classes of antidepressants on subsequent dementia: A nationwide cohort study in Taiwan (2017) · cites this paper as [36]
In the citing paper
“However, if symptoms of mild or moderate intensity are present, clinical trials indicate that benefits may be minimal or non-superior to placebo,58 whereas melancholic patients are likely to respond relatively well to pharmacotherapy.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [52]
In the citing paper
“Only 37% of patients reached remission and the proportion that responded and stayed well for a year was 15%.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [52]
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“2008;50:428–436) M ajor depressive disorder (MDD) is highly prevalent(1,2) and among the top 10 causes of disability worldwide.(3) Many clinicians under recognize and undertreat MDD,(4) despite substantial evidence that supports the efficacy and effectiveness of pharmacological and psychotherapeutic interventions.”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 4×
“Data from clinical trials suggest that an adequate trial for most patients is in the range of 4 to 8 weeks to demonstrate response, although the full benefit may not be realized until 12 weeks of acute treatment, especially for chronic depression.(7) As patients continue to exhibit an almost complete lack of response…”
BackgroundMethodInfluentialSelf-citationPrevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy.
Teasdale, J. D., Segal, Z. V., Williams, J. M. G., Ridgeway, V. A., Soulsby, J. M., & Lau, M. A. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.4.615 · Cited by 3,236
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695
Teasdale, J. D., Segal, Z., & Williams, J. M. G. (1995) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)e0011-7 · Cited by 1,349
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 5×
“Sequenced treatment alternatives to relieve depression study (STAR*D) was designed to assess a sequence of treatments for representative patients with MDD.45 Although STAR*D found few substantial differences in any of the treatments for those who failed to reach remission with citalopram, several important generalizab…”
BackgroundMethodInfluentialSelf-citationRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Overall, the odds ratio of continuation and maintenance antidepressant treatment preventing depressive relapse over 12 months reduces the odds of relapse by 70% compared with placebo-substitution (after acute response).(18) But longterm compliance with antidepressant treatment presents a challenge for many patients, w…”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Diagnostic accuracy of the mood module of the patient health questionnaire: a systematic review
Wittkampf, K. A., Naeije, L., Schene, A. H., Huyser, J., & van Weert, H. C. (2007) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.06.004 · Cited by 493
Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders
FAVA, G. A., RAFANELLI, C., CAZZARO, M., CONTI, S., & GRANDI, S. (1998) · Psychological Medicine · doi:10.1017/s0033291797006363 · Cited by 427 · cited 1×
“This modified approach was tested in a study that suggested that WBT might well prevent recurrence in depression.(50) In that trial, 40 patients with a history of recurrence were first treated to remission with medications, and then were randomized to either clinical management or WBT during the continuation phase; of…”
MethodRush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385
Self-citationHemeryck, A., & Belpaire, F. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 368
Bupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 4×
“Four of six randomized clinical trials found duloxetine to be superior to placebo for the acute treatment of MDD.(33,34) Several studies have found that duloxetine is effective for the pain complaints associated with depression.”
BackgroundInfluential(2001) · PubMed · Cited by 303
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
Predictors of Drug Response in Depression
Joyce, P. R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010091014 · Cited by 280
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Detke, M. J., Lu, Y., Goldstein, D. J., McNamara, R. K., & Demitrack, M. A. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00060-2 · Cited by 279
Fava, M., Judge, R., Hoog, S. L., Nilsson, M. E., & Koke, S. C. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1109 · Cited by 263
Self-citationMajor depressive subtypes and treatment response
Fava, M., Uebelacker, L. A., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00440-4 · Cited by 247 · cited 2×
“Patients who have anxious symptoms or anxious comorbid conditions respond less well to all of the antidepressants.(7,21)”
BackgroundSelf-citationDuration of Antidepressant Drug Treatment: What Is an Adequate Trial?
Quitkin, F. M. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790140028003 · Cited by 232
Trazodone for antidepressant-associated insomnia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1069 · Cited by 227 · cited 6×
“Paroxetine has also been associated with greater weight gain compared to the other SSRIs.24–26 The SSRIs undergo hepatic metabolism and renal elimination, with more than 90% of the parent compound inactivated.”
BackgroundInfluentialSelf-citationMETABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS
Lantz, R. J., Gillespie, T. A., Rash, T. J., Kuo, F., Skinner, M., Kuan, H.-Y., & Knadler, M. P. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1142 · Cited by 207
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
Fava, M., Mulroy, R., Alpert, J., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198
Self-citationBrannan, S. K., Mallinckrodt, C. H., Brown, E. B., Wohlreich, M. M., Watkin, J. G., & Schatzberg, A. F. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.04.011 · Cited by 181
Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1500 · Cited by 172
Raeder, M. B., Bjelland, I., Vollset, S. E., & Steen, V. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1219 · Cited by 171
Atypical Depression: A Valid Clinical Entity?
Stewart, J. W., McGrath, P. J., Rabkin, J. G., & Quitkin, F. M. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30161-8 · Cited by 152
Papakostas, G. I., Petersen, T. J., Nierenberg, A. A., Murakami, J. L., Alpert, J. E., Rosenbaum, J. F., & Fava, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0212 · Cited by 148
Self-citationAmsterdam, J. D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0216 · Cited by 147
D, M. F. M., Rosenbaum, J. F., HOOG, S. L., Tepner, R. G., Kopp, J. B., & Nilsson, M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00131-7 · Cited by 140
Effects of cognitive therapy on psychological symptoms and social functioning in residual depression
Scott, J., Teasdale, J. D., Paykel, E. S., Johnson, A. L., Abbott, R., Hayhurst, H., Moore, R., & Garland, A. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.5.440 · Cited by 139
PERRY, P. J., ZEILMANN, C., & ARNDT, S. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00002 · Cited by 138
Antidepressant Discontinuation Syndrome
(2017) · The SAGE Encyclopedia of Abnormal and Clinical Psychology · doi:10.4135/9781483365817.n77 · Cited by 134
Papakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., Fava, M., & Nierenberg, A. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1017 · Cited by 125
Self-citationCourse and treatment of atypical depression.
Nierenberg, A. A., Alpert, J. E., Pava, J. A., Rosenbaum, J. F., & D, M. F. M. (1998) · PubMed · Cited by 119
Self-citationHudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.696 · Cited by 115
Lieberman, J. A., Greenhouse, J. B., Hamer, R. M., Krishnan, K. R. R., Nemeroff, C. B., Sheehan, D. V., Thase, M. E., & Keller, M. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300571 · Cited by 109
Chronological Milestones to Guide Drug Change: When Should Clinicians Switch Antidepressants?
Quitkin, F. M. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090031005 · Cited by 107
Nortriptyline for Treatment-Resistant Depression
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Kelly, K. E., Iacoviello, B. M., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0108 · Cited by 106
Self-citationSchatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 94
Self-citationRevisiting monoamine oxidase inhibitors.
Krishnan, K. R. R. (2007) · PubMed · Cited by 82
Nierenberg, A. A., Petersen, T., & Alpert, J. E. (2003) · PubMed · Cited by 80
Self-citationReimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80060-x · Cited by 79
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
D, M. F. M., Rappe, S., Pava, J. A., Nierenberg, A. A., Alpert, J. E., & Rosenbaum, J. F. (1995) · PubMed · Cited by 63
Self-citationMirtazapine: a review of its clinical efficacy and tolerability
Szegedi, A., & Schwertfeger, N. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.4.631 · Cited by 57
Dose-Response Relationship With Venlafaxine
KELSEY, J. E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00005 · Cited by 48
Pharmacotherapy of Mood Disorders and Treatment Discontinuation
LADER, M. H. (2007) · Drugs · doi:10.2165/00003495-200767120-00001 · Cited by 43
Antidepressant Discontinuation Syndrome
Antai-Otong, D. (2003) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2003.00127.x · Cited by 38
Prevention of Relapse in Residual Depression by Cognitive Therapy: A Controlled Trial
Paykel, E. S., Scott, J., Teasdale, J. D., Johnson, A. L., Garland, A., Moore, R., Jenaway, A., Cornwall, P. L., Hayhurst, H., Abbott, R., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.9.829 · Cited by 20
Research works printed but not linked: 3
- Lavori, 1994, Recurrence after recovery in unipolar MDD—an observational follow-up-study of clinical predictors and somatic treatment as a mediating factor., Int J Methods Psychiatr Res, 4, 211
- Roose, 1989, Cardiovascular effects of tricyclic antidepressants in depressed patients., J Clin Psychiatry Monogr, 7, 1
- 1984, Anonymous, priapism with trazodone (Desyrel)., Med Lett Drugs Ther, 26, 35
Cited by
Comorbidity: a network perspective
Cramer, A. O. J., Waldorp, L. J., van der Maas, H. L. J., & Borsboom, D. (2010) · Behavioral and Brain Sciences · doi:10.1017/s0140525x09991567 · Cited by 1,575
Siwek, M., Dudek, D., Paul, I. A., Sowa-Kućma, M., Zięba, A., Popik, P., Pilc, A., & Nowak, G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.014 · Cited by 210
Bewernick, B. H., Kayser, S., Gippert, S. M., Switala, C., Coenen, V. A., & Schlaepfer, T. E. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.01.581 · Cited by 156
“Furthermore, relapse (defined as a new depressive episode within six months after remission) [21] is often used in DBS studies in the sense of “losing the 50% response status”.”
BackgroundMethodInfluentialFava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
“most widely prescribed class of antidepressants [8].”
Metadata
- Authors
- Nierenberg, A. A., Ostacher, M. J., Huffman, J. C., Ametrano, R. M., Fava, M., & Perlis, R. H.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Nierenberg, Andrew A.
- Venue
- Journal of Occupational & Environmental Medicine
- Published
- 2008-04
- Volume
- 50
- Issue
- 4
- Pages
- 428-436
- ISSN
- 1076-2752 (ISSN-L)
- OpenAlex
- W2116033122
- Cited by
- 70
- References
- 54
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 9 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 3 · 2012: 6
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Occupational and Environmental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, major depressive disorder, antidepressant efficacy, selective serotonin reuptake inhibitors, norepinephrine reuptake inhibitors, dopamine reuptake inhibitors, monoamine oxidase inhibitors, treatment-resistant depression, antidepressant augmentation, psychotherapy, remission, long-term treatment
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.